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Abstract
Introduction Basal-like breast cancers (BLBCs) are very
aggressive, and present serious clinical challenges as there are
currently no targeted therapies available. We determined the
regulatory role of Y-box binding protein-1 (YB-1) on epidermal
growth factor receptor (EGFR) overexpression in BLBC, and the
therapeutic potential of inhibiting EGFR. We pursued this in
light of our recent work showing that YB-1 induces the
expression of EGFR, a new BLBC marker.
Methods Primary tumour tissues were evaluated for YB1
protein expression by immunostaining tissue microarrays, while
copy number changes were assessed by comparative genomic
hybridization (CGH). The ability of YB-1 to regulate EGFR was
evaluated using luciferase reporter, chromatin
immunoprecipitation (ChIP) and gel shift assays. The impact of
Iressa on monolayer cell growth was measured using an
ArrayScan VTI high-throughput analyser to count cell number,
and colony formation in soft agar was used to measure
anchorage-independent growth.
Results YB-1 (27/37 or 73% of cases, P = 3.899 × 10-4) and
EGFR (20/37 or 57.1% of cases, P  = 9.206 × 10-12) are
expressed in most cases of BLBC. However, they are not
typically amplified in primary BLBC, suggesting overexpression
owing to transcriptional activation. In support of this, we
demonstrate that YB-1 promotes EGFR reporter activity. YB-1
specifically binds the EGFR promoter at two different YB-1-
responsive elements (YREs) located at -940 and -968 using
ChIP and gel shift assays in a manner that is dependent on the
phosphorylation of S102 on YB-1. Inhibiting EGFR with Iressa
suppressed the growth of SUM149 cells by ~40% in
monolayer, independent of mutations in the receptor. More
importantly anchorage-independent growth of BLBC cell lines
was inhibited with combinations of Iressa and YB-1
suppression.
Conclusion We have identified for the first time a causal link for
the expression of EGFR in BLBC through the induction by YB-
1 where it binds specifically to two distinguished YREs. Finally,
inhibition of EGFR in combination with suppression of YB-1
presents a potential opportunity for therapy in BLBC.
BAC = bacterial artificial chromosome; BLBC = basal-like breast cancer; CGH = comparative genomic hybridisation; ChIP = chromatin immunopre-
cipitation; ck5/6 = cytokeratin 5/6; DMSO = dimethyl sulphoxide; EGFR = epidermal growth factor receptor; EMSA = electrophoretic mobility shift 
assay; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; PR = progesterone receptor; 
SMRT = submegabase resolution tiling; TMA = tumour tissue microarray; YB-1 = Y-box binding factor-1; YRE = YB-1 responsive element.Breast Cancer Research    Vol 9 No 5    Stratford et al.
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Introduction
Identifying molecular targets for aggressive types of breast
cancer is a milestone in the pursuit of individualized therapies.
Gene-expression profiling of primary tumours has led to the
following subcategories: luminal A, luminal B, the human epi-
dermal growth factor receptor 2 (HER2) and the basal-like
subtypes [1]. Our attention was drawn to the basal-like sub-
type, because these tumours do not respond to available tar-
geted therapies and patients often die within two years of
diagnosis [1,2]. Approximately 16% of all breast cancers are
basal-like [3]; this corresponds to 46,400 women among the
~290,000 women in North America who will be diagnosed
with breast cancer each year. What sets these tumours apart
is that unlike many breast cancers, basal-like tumours do not
express the estrogen receptor (ER) or progesterone receptor
(PR), nor do they have amplified HER2. In the clinic, these
tumours are often referred to as 'triple negative'. Women with
triple negative tumours are not eligible for treatments that tar-
get ER (tamoxifen, aromatase inhibitors) or HER2 (trastuzu-
mab). Instead they are treated with conventional
chemotherapies, which have limited efficacy and many side
effects. Therefore, it is critically important to identify alternative
therapeutic strategies for basal-like breast cancer (BLBC).
We recently found that the transcription factor, Y-box binding
protein-1 (YB-1), protein is commonly expressed in ER-nega-
tive breast cancers [4], and loss of this receptor is one of the
hallmarks of BLBC [3,5]. More recently, YB-1 was pulled out
of a screen from the BLBC cell line SUM149 in an attempt to
identify genes that promote malignant transformation and
tumour cell growth [6]. It has also been shown recently that
epidermal growth factor receptor (EGFR) is highly expressed
in approximately 50% of BLBCs [7]. Interestingly, YB-1 was
originally isolated as a transcription factor that bound to
enhancer sites on the EGFR gene, a finding that could explain,
at least in part, why it promotes the growth of breast tumour
cells [8]. In keeping with this possibility, Berquin et al.
expressed YB-1 in mammary epithelial cells and observed a
concomitant induction of EGFR [6]. We demonstrated in
MCF-7 (ER-positive breast cancer cells) that overexpression
of YB-1 leads to an increase in the levels of EGFR mRNA and
protein [4]. This depends on the phosphorylation of YB-1 at
S102 [4]. The YB-1 S102 site is located in the DNA-binding
domain, suggesting that the effect on EGFR expression was
likely to be through transcriptional regulation. We demon-
strated that Akt binds directly to YB-1 and phosphorylates the
S102 site, an observation that was subsequently confirmed in
NIH3T3 cells [9]. We now believe that Akt is one of several
kinases capable of phosphorylating the S102 site of YB-1. In
support of this idea, inhibition of the kinase mTOR with
rapamycin also inhibits YB-1 phosphorylation [9]. To under-
stand this further, we demonstrated that YB-1 binds directly to
the EGFR promoter within the first 1 kb of the transcription
start site, and this occurs in a phosphorylation-dependent
manner [4]. Consistent with these preclinical developments,
we found that YB-1 is strongly correlated with EGFR in pri-
mary breast tumours by screening a tissue microarray of ~490
cases [4]. More recently, we have confirmed this observation
in a cohort of ~2,222 primary breast tumours. In this study,
YB-1 and EGFR are once again tightly correlated (P = 1.414
× 10-24; data not shown).
As both YB-1 and EGFR are expressed in BLBC, we ques-
tioned whether there was a relationship between these two
genes in this particular subtype of breast cancer. First, we
determined whether the overexpression was caused by gene
amplification, and then further dissected the regulatory rela-
tionship between the two. Finally, we addressed whether
inhibiting EGFR with Iressa (also referred to as ZD1839 or
gefitinib) would slow the growth of BLBC.
Materials and methods
Tumour tissue microarrays and cluster analysis
Patients in this cohort and their tumours have been previously
described [10], as have the staining conditions for YB-1,
HER2, ER and PR [10]. EGFR and CK5/6 staining was per-
formed according to Nielsen et al. [7]. In total, we had inter-
pretable data on these proteins from 285/438 total breast
cancer cases. For our analysis, YB-1 scored as 0 or 1 was
considered negative, and 2 or 3 was considered positive. Data
was filtered to exclude patients who were missing diagnostic
or survival information. Results were considered statistically
significant with P < 0.05. The data was analysed using SPSS
software (Chicago, Illinois, USA).
Comparative genomic hybridization
Ten formalin-fixed and paraffin-embedded archival BLBC
cases from the Vancouver General Hospital archival TMA438
series were identified based on a distinct immunohistochemi-
cal (IHC) staining pattern (ER-, HER2-, PR-, CK5/6+). Tissue
cores (1.5 mm) extracted from the source blocks were treated
with xylene and ethanol, as described by Garnis et al. [11].
Samples were placed into DNA lysis buffer comprised of 10
mM Tris, 50 mM NaCl, 1 mM EDTA, 0.5% SDS placed at
55°C, and digested with proteinase K (Invitrogen, Carlsbad,
C a l i f o r n i a ,  U S A )  o v e r  a  p e r i o d  o f  4 8  t o  7 2  h .  D N A  w a s
extracted as previously described, RNase-treated, and quanti-
fied by ND-1000 Full Spectrum UV/Vis Spectrophotometer
(Nanodrop, Wilmington, Delaware, USA) [11]. The ten BLBC
specimens were assayed for genetic alterations using a
whole-genome tiling path bacterial artificial chromosome
(BAC) array in comparative genomic hybridization (CGH)
experiments as previously described [12]. The submegabase
resolution tiling set (SMRT) array contained 32,433 overlap-
ping BACs-derived DNA segments that provide tiling cover-
age over the human physical genome map. All clones were
spotted in triplicate, resulting in 97,299 elements over two
sides. Hybridizations were scanned using a CCD-based imag-
ing system (Arrayworx eAuto, Applied Precision; Issaquah,
Washington, USA) and analyzed using SoftWoRx TrackerAvailable online http://breast-cancer-research.com/content/9/5/R61
Page 3 of 14
(page number not for citation purposes)
Spot Analysis software as previously described [13,14]. Data
was filtered and breakpoints were identified as previously
described by Baldwin et al. [15]. Clones with standard devia-
tions between replicate spots of >0.075 and with signal-to-
noise ratios of <3 were filtered from raw data. Genomic break-
point boundaries were defined by aCGH-Smooth software
and visual inspection. Log 2 signal intensity ratio thresholds
were used to determine regions of gain and loss, with >0.5
representing a gain and <-0.5 representing a loss.
Characterization of YB-1 and EGFR in basal-like breast 
cancer cells in vitro
184 htert cells were obtained from J. Carl Barrett at the US
National Institute of Health, and were cultured as previously
described [16]. SUM149 cells, selected because they
express markers of BLBC [17,18], were purchased from
Astrand (Ann Arbor, Michigan, USA) and were grown accord-
ing to the manufacturer's recommendation. The cells were cul-
tured in F-12 (Ham's) media (Gibco/Invitrogen, Burlington,
Ontario, USA) supplemented with 5 μg/ml insulin (Sigma,
Oakville, Ontario, Canada) 1 μg/ml hydrocortisone (Sigma),
10 mM HEPES (Sigma), 5% fetal bovine serum (Gibco/Invit-
rogen), and 100 units/ml of penicillin/streptomycin (Gibco/Inv-
itrogen). MDA-MB-468 cells were obtained from the ATCC
and cultured in Dulbecco's modified Eagle's medium, 10%
FBS and 100 units/ml penicillin/streptomycin. HCC1937
breast cancer cells, also triple negative [19], were cultured in
RPMI-1640 media supplemented with 5% FBS, 10 mM
HEPES, 4.5 g/L glucose (Sigma), 1 mM sodium pyruvate
(Sigma) and 100 units/ml penicillin/streptomycin. Cells were
maintained at 37°C in 5% CO2 and passaged every 2 days.
Proteins were isolated from log growing 184 htert, SUM149
and HCC1937 cells using an ELB buffer [4]. YB-1, EGFR and
actin were detected by immunoblotting. The YB-1 polyclonal
antibody (courtesy of Colleen Nelson, University of British
Columbia, Vancouver, Canada) was used at a dilution of
1:10,000. The EGFR monoclonal (clone 6F1, StressGen, San
Diego, California, USA) and actin (Sigma, St Louis Missouri,
USA) antibodies were diluted 1:1000.
Chromatin immunoprecipitation
SUM149 cells were plated at a density of 1 × 107 in a 150 mm
dish and YB-1-promoter complexes were isolated by chroma-
tin immunoprecipitation (ChIP) as previously described [4].
The primers to each of the potential YB-1 binding sites were
previously described [4]. The EGFR promoter was amplified
(40 cycles) using primers that span regions within the first 2
kb upstream of the start site. The input DNA was diluted four-
fold before amplification.
Serial ChIP to determine YB-1 phosphorylation status
To determine whether YB-1 is serine phosphorylated at the
EGFR promoter, complexes were isolated as described above
with the chicken YB-1 antibody and then eluted by incubation
in 10 mmol/L DTT at 37°C for 30 min with agitation. The eluate
was diluted 1:50 with buffer (20 mmol/L Tris (pH 8.1), 150
mmol/L NaCl, 2 mmol/L EDTA, and 1% Triton X-100) and re-
immunoprecipitated with 5 μg of anti-phosphoserine antibody
(StressGen) overnight at 4°C. Secondary immunocomplexes
were incubated with salmon sperm DNA/protein A agarose for
2 h at 4°C. Subsequent steps followed the ChIP protocol
described previously by [4] and PCR was performed with
primers to the EGFR 2a site as described above. To test for
non-specific binding species, matched IgY and IgG were incu-
bated with an equal amount of SUM149 cross-linked DNA.
The sample was then processed as described above and
amplified with primers to EGFR 2a. The input DNA was also
introduced as a positive control.
ChIP was also performed using a phospho-YB-1 (S102) anti-
body (in collaboration with Peter Mertens, Germany). The pep-
tide sequence and supportive data demonstrating the
specificity of the antibody was recently described by us [20].
The immunoprecipitation was carried out as described above
for YB-1 with protein G-agarose used in place of PreciPhen
beads and rabbit IgG instead of IgY.
Electrophoretic mobility shift assay (EMSA)
Nuclear and cytoplasmic protein was extracted from log-grow-
ing SUM149 cells, MDA-MB-468 or HCC1937 cells using the
NE-PER nuclear and cytoplasmic extraction reagents (Pierce
Biotechnology, Rockford, Illinois, USA) following the manufac-
turer's protocol. Briefly, cells were centrifuged to obtain a
packed cell volume and lysed in ice cold CER I with protease
inhibitors. Following 5 min on ice, ice-cold CER II was added
and samples centrifuged at 13,000 g for 10 min. Cytoplasmic
protein was retained and the pellet re-suspended in ice-cold
NER with protease inhibitors. The sample was incubated on
ice for 40 min with frequent mixes and then centrifuged at
13,000 g for 10 min. The supernatant containing nuclear pro-
tein was stored. Proteins were quantified using the Bradford
Assay. EMSAs were carried out using the Lightshift Chemilu-
minescent EMSA kit (Pierce Biotechnology), following the
manufacturer's protocol. 5' Biotin-labelled complementary oli-
gonucleotides with the following sequences, wild-type (-979
to -937) TTCACACATTGGCTTCAAAGTACCCATGGCT-
GGTTGCAATAAACAT, -968 mutant 5'-
TTCACACCCCCGCTTCAAAGTACCCATGGCTGGTT-
GCAATAAACAT, -940 mutant 5'-
TTCACACATTGGCTTCAAAGTACCCATGGCTGGTT-
GCCCCAAACAT and double mutant 5' -
TTCACACCCCCGCTTCAAAGTACCCATGGCTGGTT-
GCCCCAAACAT were annealed to form double stranded
DNA. Binding reactions consisted of 1 × binding buffer, 50
ng/μl poly dIdC, 20 fmol Biotin-labeled DNA and 5 μg nuclear
protein in a 20 μl reaction. Competition reactions included 16
pmol unlabelled oligonucleotide (800-fold excess), and 1 μg
chicken anti-YB-1 antibody was included to determine YB-1
involvement. An antibody to CREB (1 μg) was introduced as aBreast Cancer Research    Vol 9 No 5    Stratford et al.
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negative control. The protein was incubated with the
unlabelled oligonucleotide or the antibody for 20 min before
the addition of the biotin-labelled oligonucleotide. The sam-
ples were incubated for 20 min at room temperature. The reac-
tion mixture was run on a 6% non-denaturing polyacrylamide
gel and transferred to a positively charged nylon membrane
(Amersham Biosciences, Little Chalfont, UK). DNA was
crosslinked to the membrane at 120 mJ/cm2 using a UV-light
crosslinker (Stratalinker, Stratagene, La Jolla, California, USA)
and detected using chemiluminescence (Pierce
Biotechnology).
Nuclear extraction of primary BLBC tumours
Tissue slices from six BLBC tumour specimens were obtained
from the British Columbia Cancer Agency, Canada. Nuclear
fractions were extracted using the NE-PER nuclear and cyto-
plasmic extraction reagents as described above. Since tissue
was limited the samples were pooled before the nuclear
extraction step. Electrophoretic mobility shift assays were car-
ried out as described above with 10 μg protein.
EGFR luciferase assay
To determine whether YB-1 has a direct effect on EGFR pro-
moter activity the normal breast cell line, 184 htert, was trans-
fected with a 1 kb EGFR promoter construct [21] (courtesy of
Alfred C Johnson US National Cancer Institute, Massachu-
setts, USA), a renilla expression vector, pRL-TK (Promega,
Madison, Wisconsin, USA), and a YB-1 expression plasmid, a
YB-1 S102 mutant (A102) or empty vector. The cells were
plated in 6-well plates (4 × 105 cells/well) and transfected with
a total of 1.5 μg DNA using lipofectamine 2000 (Invitrogen).
Cells were harvested 24 h post-transfection in 1 × PLB buffer
(Promega), and luciferase activity measured. All luciferase
measurements were normalized to the renilla reading from the
same sample. To carry out the inverse experiment the Fast-For-
ward Protocol provided with the HiPerFect Transfection Rea-
gent (Qiagen, Mississauga, Ontario, USA) was used to
achieve knockdown of YB-1 in SUM149 and HCC1937 cells
using small interfering RNA (siRNA) (for control and YB-1
siRNA sequences see [4]). Briefly, cells were seeded at 4 ×
105 cells/well of a 6-well plate in 2 ml media shortly before
transfection. siRNA was diluted to 100 μl in serum-free media
to achieve a final concentration of 5 nM (SUM149) or 20 nM
(HCC1937), and 3 μl HiPerFect was added. Samples were
vortexed, incubated at room temperature for 10 min, and then
added drop-wise to the cells. At 48 h the cells were re-plated
in 6-well plates (4 × 105 cells/well and transfected with the
pER1, pRL-TK and empty vector and harvested at 24 h post-
transfection as described above. Cell lysates were also col-
lected at the time of re-plating to ensure successful knock-
down of YB-1. The experiments were performed in triplicate on
two separate occasions. The results are reported as the aver-
age of two experiments.
Cell viability following treatment with Iressa
SUM149 breast cancer cells were plated in 96-well plates (5
× 103 cells/well) and incubated for 24 h at 37°C in the growth
media described above. Cells were treated with Iressa (iso-
lated from tablets purchased from Astra Zeneca and kindly
provided by Ching-Shih Chen, Ohio State University, USA) at
the following concentrations; 0, 0.25, 0.5, 1 and 2 μM with
dimethyl sulphoxide (DMSO) as vehicle control. Cell number
was ascertained after 72 h treatment. Cells were washed in
PBS and then incubated with Hoechst dye (1 μg/ml) for 15
mins. Nuclei counts/well were determined using the Array-
Scan VTI high throughput analyser. Statistical analyses were
carried out using the Student t test with significance accepted
when P < 0.05.
Growth in soft agar
SUM149 cells were plated at a density of 2.5 × 104 in a 24-
well plate in 0.6% agar, as previously described [10] and sup-
plemented with Iressa in the cell layer (concentrations as
above). HCC1937 cells were treated with CTRL and YB-1
siRNA for 48 hours and then plated at a density of 10 × 103 in
0.6% agar. At the time of seeding the agar was supplemented
with Iressa (0.25 to 2 μM) as described earlier. Colonies
developed over 30 days and were then counted. Each experi-
ment was performed in replicates of four and repeated twice.
EGFR sequencing from SUM149 cells
Genomic DNA was isolated from 2 × 107 SUM149 cells using
phenol chloroform extraction followed by alcohol precipitation
(modified from [22]). DNA was quantified in a UV spectropho-
tometer. EGFR exons 1 to 28 were amplified by PCR and
sequenced using standard techniques used by the British
Columbia Cancer Agency Michael Smith Genome Sciences
Centre. PCR primers were designed using human genome ref-
erence sequence acquired from the UCSC Genome Browser
[23] ([24]) and the Primer3 program [25]. The PCR primer
sequences are listed in Additional file 1. Each PCR reaction
was performed on 10 ng of SUM149 DNA and the products
were visualized on a 2% agarose gel. PCR products were
cleaned up using Ampure magnetic beads (Agencourt, Bev-
erly, Massachusetts, USA) and sequenced using a standard
BigDye Terminator v3.1 cycle sequencing chemistry and
Applied Biosystems (Foster City, California, USA) 3730 × l
DNA Analyzer.
Results
YB-1 and EGFR amplification is not common in BLBC, 
indicating changes in transcriptional control
Breast tumour tissue microarrays were profiled to evaluate the
frequency to which EGFR and YB-1 are expressed in triple
negative breast cancers. Such tumours express YB-1 and
EGFR in 73% and 57.1% of the BLBC cases, respectively
(Table 1). Representative immunohistochemical images for
both EGFR and YB-1 are shown in Figure 1. As indicated by
the arrowheads, YB-1 was expressed in the cytoplasm as wellAvailable online http://breast-cancer-research.com/content/9/5/R61
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as the nucleus. Although we have established that YB-1 and
EGFR are frequently expressed in triple-negative breast can-
cers, it is not clear why this occurs. One possibility is that
these genes are both amplified during the development of
BLBC. To study this, we isolated DNA from 10 primary BLBCs
and evaluated them for copy number changes by array CGH
using a genome-spanning tiling path array (SMRT) [26]. Copy
number changes were not observed at the YB-1  locus
(1p34.2) or the EGFR locus (7p13-11.2) in 10/10 and 9/10
cases, respectively (Figure 2). A borderline 10 Mb segmental
gain was present in one (referred to as BLC9) of the 10 cases
at 7p13-11.2 encompassing many gene loci including EGFR
(Figure 2). The lung cancer adenocarcinoma cell line
(HCC827), known to have amplified EGFR, was evaluated as
a positive control (Figure 2). Overall neither YB-1 nor EGFR
were commonly amplified, suggesting expression is increased
owing to promoter activation.
YB-1 regulates the expression of EGFR in BLBC
To perform functional investigations into the role of YB-1 and
EGFR in BLBC, we tested the SUM149 and HCC1937 cell
lines, which have a basal phenotype [17-19,27]. Initially the
levels of YB-1 and EGFR were compared between 184 htert
(immortalized breast epithelial cells) and the cancer cells.
SUM149 and HCC1937 cells had high levels of YB-1 and
EGFR compared with the 184 htert cells (Figure 3a). Building
on the observation that YB-1 binds to the EGFR promoter
within the first 1 kb of the start site [4], we then investigated
Table 1
YB-1 is highly expressed in triple negative breast cancer
Marker Correlation Likelihood ratio value
YB-1 P = 3.899 × 10-4 12.58
N = 27/37 (73%)
EGFR P = 9.206 × 10-12 46.491
N = 20/37 (57.1%)
Y-box binding protein 1 (YB-1) is expressed in 73% of triple negative breast cancers in the TMA438. Epidermal growth factor receptor (EGFR) is 
expressed in 57.1% of these cases.
Figure 1
Epidermal growth factor receptor (EGFR) and Y-box binding protein 1 (YB-1) are detected in basal-like breast cancer specimens on a tumour tissue  microarray Epidermal growth factor receptor (EGFR) and Y-box binding protein 1 (YB-1) are detected in basal-like breast cancer specimens on a tumour tissue 
microarray. (a) EGFR-negative staining (40×). (b) Brown cells indicate EGFR positivity (40×), a segment of the core is magnified at 200×. (c) YB-1-
negative staining (40×). (d) Brown staining indicates YB-1 positivity (40×), which is detected in both the nucleus and cytoplasm (arrowheads 
200×).Breast Cancer Research    Vol 9 No 5    Stratford et al.
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whether there was a causal link between YB-1 and the expres-
sion of EGFR in the SUM149 and HCC1937 cells. First, we
have determined that YB-1 was able to stimulate EGFR pro-
moter activity using a luciferase reporter construct containing
the first 1 kb of the EGFR promoter. Immortalized breast cells
(184 hterts) confirmed not to express YB-1 (Figure 3a) trans-
fected with a hYB-1 plasmid increased EGFR luciferase activ-
ity 1.5-fold compared with the control cells (P = 0.04, N = 6)
(Figure 3b). Interestingly, when cells were transfected with the
YB-1 mutant (A102) that could no longer be phosphorylated
at S102, there was a significant attenuation in reporter activity
compared with control cells (P = 0.013, N = 6) (Figure 3b).
We then addressed whether silencing the high levels of YB-1
in the SUM149 and HCC1937 cells would attenuate EGFR
reporter activity. YB-1 was knocked down with siRNA for 48 h
and then transfected with the EGFR reporter. Under these
conditions, we observed a 78% and 77% loss in EGFR
reporter activity in SUM149 and HCC1937 cells, respectively
(P = 4.53 × 10-5 and P = 5.98 × 10-7, N = 6) (Figure 3c,d).
Therefore, through gain-of-function and loss-of-function stud-
ies we showed that YB-1 transactivates the EGFR promoter,
and that this occurs in a manner that is dependent on the
S102 DNA binding site.
Figure 2
Basal-like breast tumours do not exhibit amplifications for epidermal growth factor receptor (EGFR) or Y-box binding protein 1 (YB-1) Basal-like breast tumours do not exhibit amplifications for epidermal growth factor receptor (EGFR) or Y-box binding protein 1 (YB-1). Primary breast 
tumours were evaluated for genetic amplifications using SMRT array CGH. DNA was isolated from ten primary basal-like breast tumours and 
genomic profiles were generated by submegabase resolution tiling array comparative genomic hybridisation. There was no obvious gain of copy 
number on chromosomes 1 or 7, representing the loci for YB-1 and EGFR, respectively. The exception to this trend was BLC9, where there was a 
large amplicon on chromosome 7. The lung adenocarcinoma cell line HCC827 was included as a positive control of EGFR amplification.Available online http://breast-cancer-research.com/content/9/5/R61
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Having demonstrated that YB-1 can transactivate EGFR we
next determined whether YB-1 interacted with the EGFR pro-
moter in the basal-like breast cancer cells to further confirm
binding observed in breast cancer cell lines that were not
basal-like [4], and to address whether this occurs in a manner
that is dependent on S102 phoshorylation using a newly
developed antibody directed at YB-1(S102) [20]. Using the
primer sets previously described [4] we show that, in SUM149
cells, YB-1 binds to the EGFR promoter within the first 1 kb,
and most strongly at the 2a site (Figure 4a, lane 2). This inter-
action is also observed in the basal-like MDA-MB-468 cells
that we have previously reported [20]. Binding did not occur
in the SUM149 cells in the regions designated 2b and 3 (Fig-
ure 4a, lanes 3 and 4). We confirmed that binding was specific
and did not bind to the IgY alone (Figure 4a, lanes 5 to 8), and
that the primers could amplify genomic input DNA (Figure 4a,
lanes 9 to 13) compared with the negative controls in which
no DNA was added to the amplification reaction (Figure 4a,
Figure 3
Y-box binding protein 1 (YB-1) regulates the expression of epidermal growth factor receptor (EGFR) in basal-like breast cancer cells Y-box binding protein 1 (YB-1) regulates the expression of epidermal growth factor receptor (EGFR) in basal-like breast cancer cells. (a) The levels 
of YB-1 and EGFR proteins were compared between immortalized breast epithelial cells, 184 htert, SUM149 and HCC1937 basal-like breast can-
cer cells. Actin was evaluated as a control for equal protein input. (b) 184 htert cells were transfected with an EGFR promoter (1 kb) luciferase con-
struct (pER1), a control renilla plasmid (pRL-TK) and either flag-EV or flag-YB-1 or flag-YB-1(A102). Luciferase and renilla activity were measured 
after 24 hours. YB-1 induced EGFR promoter activity by 1.5-fold (P = 0.04, N = 6), whereas the A102 mutant did not. (c) SUM149 cells were 
treated with YB-1 small interfering RNA (siRNA) (5 nM) for 48 h. The cells were then transfected with the EGFR reporter for 24 h and compared 
with the empty vector. Loss of YB-1 expression resulted in a 78% decrease in EGFR reporter activity (P = 4.53 × 10-5, N = 6). Inset: evidence that 
siRNA targeting YB-1 causes a decrease in expression of the protein. Actin was used as a loading control. (d) The same experiment was repeated 
using HCC1937 cells treated with 20 nM YB-1 siRNA for 48 h. Loss of YB-1 expression resulted in a 77% reduction in EGFR promoter activity (P 
= 5.98 × 10-7, N = 6).
(d)Breast Cancer Research    Vol 9 No 5    Stratford et al.
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lanes 13 to 16). This binding pattern is in keeping with our pre-
vious work showing that YB-1 binds to the EGFR promoter
within the first 1 kb in a manner that was dependent on phos-
phorylation at S102 [4]. As the phosphorylation status of YB-1
affected its ability to transactivate EGFR, we assessed
whether this was also the case in the interaction between the
YB-1 and 2a site of the promoter. We therefore questioned
whether YB-1 is serine phosphorylated when it binds to the 2a
site. To address this, we initially developed serial ChIP proto-
col, whereby YB-1 was initially used to pulldown protein–DNA
complexes, and the resulting samples were then immunopre-
cipitated with an antibody to phospho-serine. Using this
method we were able to show that YB-1 is serine phosphor-
ylated when it binds to the 2a site (Figure 4b). More recently,
we have had the opportunity to test a new polyclonal antibody
raised against YB-1(S102) specifically [20]. In this case, bind-
ing to the 2a site is also observed (Figure 4c) further support-
ing the idea that YB-1 is serine phosphorylated at S102 when
it binds to the EGFR promoter.
The ability of YB-1 to bind to the EGFR promoter specifically
at the 2a region was further confirmed using gel shift assays.
Nuclear extracts from SUM149, MDA-MB-468 and
HCC1937 cells were incubated with a biotin-labelled oligonu-
cleotide probe spanning -979 to -934 of the EGFR promoter
(Figure 5a). MDA-MB-468 and HCC1937 cells were used as
an additional basal-like cancer cell lines as they are triple neg-
ative and they overexpress EGFR. Compared with the
unbound probe (Figure 5b, lanes 1, 5 and 10), the introduction
of the nuclear extract from all cell lines produced intense bind-
ing to the EGFR promoter (Figure 5b, lanes 2, 6 and 11) that
could be competitively inhibited with unlabelled probe (Figure
5b, lanes 3, 7 and 12). Co-incubation of the nuclear extract
with a YB-1 antibody caused a supershift (Figure 5b, lanes 4,
8 and 13), an effect not observed when an unrelated CREB
antibody was used in the same reaction (Figure 5b, lanes 9
and 14); therefore, we validated our ChIP results by
demonstrating that YB-1 binds directly to the EGFR promoter.
We have also been able to show that YB-1 binds to the 2a
region of the EGFR promoter in primary BLBC cancer sam-
ples (Figure 5c, lane 2). This interaction could be competed off
with unlabelled oligo (Figure 5c, lane 3) and supershifted
using the YB-1 antibody (Figure 5c lane 4). To further dissect
YB-1 binding within the 2a region we designed biotin-labelled
oligonucleotides in which the YB-1-responsive elements
(YREs) were mutated at -968, -940 or both sites (Figure 5a).
Losing either of the YREs resulted in less YB-1 binding com-
pared with the wild-type EGFR promoter sequence (Figure
5d). These data verify that the -968 and -940 binding sites are
bona fide YREs. Together these data show that YB-1 is able
to bind to the first 1 kb of the EGFR promoter, and this leads
to transactivation in a phosphorylation dependent manner.
Figure 4
Y-box binding protein 1 (YB-1) binds to the epidermal growth factor  receptor (EGFR) promoter Y-box binding protein 1 (YB-1) binds to the epidermal growth factor 
receptor (EGFR) promoter. (a) Chromatin immunoprecipitation was 
performed on SUM149 cells. YB-1 binds to the EGFR promoter in the 
basal-like cells where the 2a loci is the preferred binding site (lane 2). 
Weak binding was also detected with the 1b primers (lane 1). No bind-
ing was observed in the 2b or 3 sites (lanes 3 to 4), nor was there any 
non-specific binding detected in the IgY negative controls (lanes 5 to 
8). Input DNA was diluted fourfold and amplified to demonstrate that 
the primer produced an expected product (lanes 9 to 12). The no input 
controls (lanes 13 to 16) are presented to show a lack of non-specific 
amplifications. (b) Serial ChIP was performed by sequentially pulling 
down YB-1 and then immunoprecipitating with a phospho-serine anti-
body. This demonstrated that at least some of the YB-1 is serine phos-
phorylated when bound to the EGFR 2a site. YB-1 binds to the 2a site 
(lane 1) as expected. Similarly, the phospho-serine antibody pulls down 
a complex that can be amplified with the 2a primers (lane 2). Re-ChIP 
with the YB-1 antibody and subsequently with the phospho-serine anti-
body also bound to EGFR at the 2a site (lane 3). A phospho-serine YB-
1 complex bound to the 2a site on EGFR (lane 3). Species-matched 
IgG and IgY controls were included to show that the binding was spe-
cific (lane 4). The input DNA and no DNA controls were also included 
(lanes 5 and 6). (c) ChIP was carried out using a phospho-YB-1 anti-
body (S102), and binding was detected for the EGFR 2a region (lane 
4). There was no binding observed when immunoprecipitation was per-
formed using IgG as a control (lane 3). Input DNA was diluted fourfold 
and amplified to demonstrate that the primer produced an expected 
product (lanes 5 and 6). Lane 1 is the DNA ladder.Available online http://breast-cancer-research.com/content/9/5/R61
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Figure 5
Y-box binding protein 1 (YB-1) binds to specific sites within the epidermal growth factor receptor (EGFR) promoter Y-box binding protein 1 (YB-1) binds to specific sites within the epidermal growth factor receptor (EGFR) promoter. (a) Sequence of the EGFR2a 
oligonucleotide used in the gel shift assays (-979 to -934). Highlighted sequences are the potential YB-1 binding sites. The substitutions made in 
the two mutants are given under the wild-type sequence. (b) Direct evidence for YB-1 binding to the EGFR promoter using gel shift assays. Nuclear 
extract from SUM149, MDA-MB-468 or HCC1937 cells were incubated in the presence of the EGFR oligonucleotide spanning -979 to -934. There 
was no binding in the absence of protein (lanes 1, 5 and 10), whereas the addition of the nuclear extract (lanes 2, 6 and 11) resulted in strong bind-
ing that could be inhibited with the unlabelled oligonucleotide (lanes 3, 7 and 12). The addition of a YB-1 antibody caused a supershift (lane 4, 8 and 
13) that did not occur when the non-related CREB antibody was used (lanes 9 and 14). (c) Nuclear extracts from 6 primary BLBC samples were 
pooled and used in a gel shift assay for the EGFR 2a site. Lane 1 contains EGFR2a biotin-labelled oligo only. Binding to the probe is evident in lane 
2, which was competed off in lane 3 and supershifted with a YB-1 antibody in lane 4. A CREB antibody was used to demonstrate specificity of the 
supershift (lane 5). (d) Validation of putative YB-1-responsive elements on the EGFR promoter. SUM149 nuclear extracts were incubated with either 
wild-type (lane 1) or mutant biotin oligo nucleotides (lanes 3, 4, and 5). A competition reaction was carried out against the wild-type (lane 2). nuclear 
extract bound to the wild-type sequence (lane 1), but was unable to bind the mutants (lanes 3, 4 and 5).Breast Cancer Research    Vol 9 No 5    Stratford et al.
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Inhibiting EGFR suppresses the growth of BLBC cells
As there are several commercially available EGFR inhibitors
available (such as Iressa and erlotinib), we questioned
whether targeting this receptor tyrosine kinase would be effec-
tive in cells in which it is highly expressed. Monolayer cell
growth could be inhibited by up to 40% when SUM149 cells
were treated with Iressa (0 to 2 μM) for 72 h (Figure 6a); how-
ever, more interestingly, if we grew SUM149 cells in anchor-
age-independent conditions then formation of colonies, and
therefore the ability of the cells to transform, was completely
abolished in the presence of as little as 0.25 μM Iressa com-
pared with vehicle-treated cells (control 1,867 ± 363, 0.25 to
2 μM Iressa 0 ± 0) (Figure 6b). These concentrations are
achievable in patients [28] and have previously been shown to
inhibit MAP kinase signalling [29]. To confirm this observation,
we also found that low doses of Iressa inhibited signalling
through the MAP kinase pathway (data not shown). To ascer-
tain whether this sensitivity was inherent to other BLBC cell
lines we repeated the same experiment in HCC1937 cells,
and somewhat surprisingly these cells were still able to form
colonies in anchorage-independent conditions in the pres-
ence of up to 2 μM Iressa. Similarly, the MDA-MB-468 basal-
like breast cancer cells are insensitive to Iressa initially but can
be sensitized by targeting PI3 kinase with LY294002 [30]; an
observation that we independently confirmed (data not
shown). In a separate study, LY294002 has been shown to
inhibit phosphorylation of YB-1 [9]. This is in keeping with our
previous studies demonstrating that YB-1 is phosphorylated
by Akt in response to PI3 kinase activation [10]. We therefore
questioned whether knocking down YB-1 in HCC1937 cells
before treating with Iressa would be effective at reducing the
ability of these cells to grow in soft agar. The suppression of
YB-1 alone caused a 42% reduction in the number of colonies
compared with control (P = 0.0008), but there was further
significant decreases in colony number with the addition of as
little as 0.25 μM Iressa (P < 0.001 for all concentratons)(Fig-
ure 6c). Thus, our studies indicate that although some BLBC
cells may be sensitive to Iressa, for others the inhibition of YB-
1 may be necessary to sensitize the cells to drug.
We were rather surprised that the SUM149 cells were so sen-
sitive to the drug. An obvious explanation would be that these
cells express activating mutations in EGFR that would make
them sensitive to Iressa, as has been described for lung can-
cer [31]. We therefore sequenced EGFR but unexpectedly did
not find such mutations. All 28 exons coding for this gene were
amplified by PCR and sequenced. Activating mutations such
as L858R or delL747-P753insS that have previously been
reported to be associated with Iressa sensitivity [31] were not
found. However, we did identify five single-nucleotide poly-
morphisms (SNPs) in exons 12, 13, 15 and 20 (Additional file
2). There was one homozygous non-translated SNP
(rs712830), three heterozygous synonymous SNPs
(rs17290005, rs17290162 and rs17337198), and one heter-
ozygous non-synonymous SNP (rs11543848). These
dbSNPs have been previously identified for EGFR ([32]),
although their functional significance is not yet known. The
SNP of most interest is R521K, located on exon 13, because
it results in an amino acid change located in the extracellular
domain of the receptor [33].
We concluded that irrespective of 'activating mutations' in
EGFR, Iressa inhibits the growth of basal-like breast cancer
cells. In some cases, co-targeting EGFR and YB-1 may be
necessary to optimally inhibit the growth of these aggressive
breast cancer cells. Given these data, we concluded that
inhibiting EGFR and YB-1 significantly slows the growth of
BLBC cells.
Discussion
It has previously been reported that both YB-1 and EGFR are
highly expressed in aggressive forms of breast cancer [4,7]. In
this study we show that although these proteins are a feature
of BLBC, neither gene is overexpressed owing to amplifica-
tion. In further studying YB-1 as a transcription factor, we
show that it transcriptionally induces EGFR in basal-like cell
lines, which could lead to the increased expression observed.
Importantly, we have been able to pinpoint that YB-1 binds
specifically to YREs located at -968 and -940. On precisely
identifying the bona fide YREs on the EGFR promoter, we
demonstrate for the first time that binding to this region occurs
when YB-1 is phosphorylated at S102. The high levels of both
EGFR and YB-1 in BLBC begs the question of whether either
of them are potential therapeutic targets. Based on the poor
survival rates previously reported [1,2] it is clear that the BLBC
subtype represents a very aggressive form of the disease, and
EGFR is a rational target for the treatment of BLBC. In fact,
since it was reportedly associated with this subtype of breast
cancer in 2004 [7], the use of EGFR in classifying basal-like
tumours by immunohistochemistry has become widely
accepted [34,35].
We show for the first time that the EGFR inhibitor Iressa sup-
presses the growth of SUM149 cells, a model for BLBC, in
vitro at concentrations achievable in patients [28]. This is not
the case for other BLBC models, as no inhibition of anchor-
age-independent growth was evident in the HCC1937 cells
when they were treated with Iressa alone. This insensitivity is
also reported in MDA-MB-468s [30] and MDA-MB-231 cells,
another triple negative cell line with high levels of EGFR
expression [36,37]. Why the SUM149 cells alone are sensi-
tive to the drug is not clear. Several studies suggest that acti-
vating mutations in EGFR are predictive of whether inhibitors,
such as Iressa, would be effective in patients with lung cancer
[31,38]. The same could be true for breast cancer, but it is not
known whether BLBCs harbour such mutations. However, we
did sequence the entire EGFR gene from SUM149 cells and
did not find activating mutations previously described for lung
cancer. Whether the SNP at R521K influences sensitivity to
Iressa is not known, and warrants further investigation.Available online http://breast-cancer-research.com/content/9/5/R61
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Another factor that may influence the sensitivity to EGFR inhib-
itors is the level of expression of the target itself, and also the
presence of alterations in downstream signalling independent
of receptor activation. For example, both the HCC1937 [19]
and MDA-MB-468 cells [39] are PTEN null, resulting in
increased propagation of the PI3-kinase pathway. She et al.
have previously shown that by inhibiting the PI3-kinase path-
way with LY294002 they can sensitize cells to Iressa [30], and
we also found that by suppressing the expression of YB-1,
which is downstream of phospho-Akt [10], using siRNA in the
HCC1937 cells we were able to increase the effect of Iressa.
Why YB-1 sensitizes BLBC cells to Iressa is an interesting
question. YB-1 has been shown to regulate the MDR1 gene
[40,41], and thus the P-glycoprotein pump, a member of the
ABC family of transporters. This pump is involved in the efflux
of many drugs, and has been associated with resistance to
many chemotherapeutic agents [42]. We recently performed
a ChIP on chip analysis of YB-1 target genes in SUM149 cells,
and identified ~15 ABC transporter family members that were
putatively bound by YB-1, including ABCG2, ABCA5 and
Figure 6
Inhibiting epidermal growth factor receptor (EGFR) suppresses the growth of basal-like breast cancer cells Inhibiting epidermal growth factor receptor (EGFR) suppresses the growth of basal-like breast cancer cells. (a) Inhibition of EGFR with Iressa (0.25, 
0.5, 1 and 2 μM) blocks the growth of basal-like breast cancer cells by up to 40% when the cells were treated for 72 h (0.5 μM P = 0.02, 1 μM P = 
0.02, 2 μM P = 0.07). Each experiment was performed in replicates of six on two separate occasions. (b) Anchorage-independent growth was 
measured by counting colonies formed after 4 weeks exposure to Iressa or vehicle control. Representative images of colonies following each treat-
ment are shown, with average colony number/well shown underneath. The ability to form colonies was completely lost in the presence of concentra-
tions of Iressa as low as 0.25 μM in SUM149 cells. (c) The ability of HCC1937 cells to form colonies was not effected by Iressa alone; however, 
knockdown of YB-1 significantly reduced the number of colonies (P < 0.001). The addition of Iressa further reduced the number of colonies. This 
was highly significant at all concentrations (P < 0.001). Statistical analysis carried out using students t-test; *P < 0.05, **P < 0.01.Breast Cancer Research    Vol 9 No 5    Stratford et al.
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ABCC3. Studies carried out by Özvegy-Laczka et al. showed
that multidrug transporters such as ABCG2 may be involved
in the resistance to tyrosine kinase inhibitors such as Iressa by
modulating the uptake and extrusion of these drugs to and
from cells [43]. In fact, they specifically show that ABCG2, but
not mutant ABCG2, protects the lung cancer cell line A431
from Iressa-induced growth inhibition [44]. A more recent
study [45] also confirms these findings with the demonstration
of decreased intracellular accumulation of low concentrations
of Iressa (0.1 μM to 1 μM) and higher efflux with 1 μM Iressa.
Although further work is required to ascertain the mechanism
involved, the suppression of YB-1 expression could indirectly
increase the levels of these inhibitors in the cells, allowing
them to bind to their target and reduce cell growth.
Not withstanding that SUM149 cells are sensitive to Iressa,
suggesting that some BLBCs may be also, we recognize that
acquired resistance to inhibitors such as Iressa is a common
problem. There are many studies that implicate the overactiva-
tion of alternative signalling pathways, such as the insulin-like
growth factor 1 pathway [46] and MET receptor amplification,
leading to the activation of ERBB3–Akt pathway [46]. Alterna-
tively, downstream pathways can become constitutively acti-
vated, an example being KRAS, which has been reported in
lung and colon cancers [47-50]. Given this problem of
acquired resistance, and the fact that many BLBC cases will
not be sensitive, using Iressa in combination with an inhibitor
for a downstream component may provide more long-term
benefits.
Although we have established an association between YB-1
and EGFR in BLBC, it is likely that this transcription factor reg-
ulates the expression of other proteins linked to BLBC. For
example, YB-1 regulates proliferating cell nuclear antigen
(PCNA) and topoisomerase IIα [51], both of which are
expressed in BLBC [52]. In colorectal carcinomas, YB-1 and
topoisomerase IIα are co-ordinately expressed [53]. Likewise,
similar expression patterns are reported in lung cancer [54]
and synovial sarcomas [55]. More direct evidence for this
association is supported by Shibao et al. who reported that
knocking down YB-1 with antisense attenuates topoisomer-
ase IIα reporter activity [53]. These and other YB-1 target
genes are yet to be confirmed in BLBC. If PCNA and topoi-
somerase IIα are YB-1-responsive genes in BLBC, it would
explain why the expression of this transcription factor is clearly
associated with poor survival, based on work previously done
by us [4] and others [56]. There are currently no commercially
available inhibitors to YB-1. However, as YB-1 transactivates
many growth-promoting genes, and we have shown that it can
increase sensitivity to approved agents in BLBC, the question
of whether it would also be a potent therapeutic target for this
aggressive type of breast cancer is being actively pursued in
our laboratory.
Conclusion
We conclude from our data that YB-1 has a role in EGFR gene
expression in BLBC. Furthermore, we demonstrate that
tumour cell growth can be attenuated by blocking EGFR,
alone or in combination with YB-1 inhibition, providing new
possibilities for the treatment of this highly aggressive disease.
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